Kathleen N. Moore, MD, MS

Kathleen N. Moore, MD, MS, discusses how standard-of-care treatment strategies for advanced recurrent endometrial cancer have improved over time.

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates currently in development for patients with FRα-expressing ovarian cancer.

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

Kathleen N. Moore, MD, MS, discusses adverse effects associated with the use of antibody-drug conjugates for the treatment of gynecologic cancers.

Kathleen N. Moore, MD, MS, discusses the eligibility criteria for the ongoing, first-in-human, phase 1/2 study of ubamatamab, a MUC16- and CD3-targeted bispecific antibody, alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Kathleen Moore, MD, discusses current standard of care in treating ovarian cancer.

Kathleen N. Moore, MD, associate director for clinical research, gynecologic oncologist at The Stephenson Cancer Center, The University of Oklahoma, explores the impact of the SOLO-1 trial in the field of ovarian cancer, in particular, the benefits olaparib provides and the light it shines on the importance of using genetic testing to inform treatment decisions.

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses challenges with immunotherapy agents in the treatment of patients with ovarian cancer.

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations of immunotherapy with PARP inhibitors for patients with BRCA-mutated ovarian cancer.